Date: 2015-12-06
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, December 5-8, 2015
Company: Seattle Genetics (USA - WA)
Product: SGN-CD19B
Action
mechanism: antibody drug conjugate. SGN-CD19B is an antibody drug conjugate that targets CD19 and utilizes one of Seattle Genetics’ proprietary payloads, a pyrrolobenzodiazepine (PBD) dimer.
Disease: B cell malignancies
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On December 6, 2015, Seattle Genetics highlighted preclinical data from a novel antibody-drug conjugate (ADC) program called SGN-CD19B in B-cell malignancies at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015. The company plans to advance SGN-CD19B into a phase 1 trial in 2016. SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies (Abstract #594, oral presentation on Monday, December 7, 2015 at 11:45 a.m.) A preclinical analysis evaluated the activity of SGN-CD19B, a new ADC consisting of an anti-CD19 antibody attached to a highly potent DNA binding agent called a PBD dimer, in multiple B-cell malignancy models. Data to be presented in an oral session demonstrate that SGN-CD19B exhibits antitumor activity against a broad panel of CD19-expressing B-cell malignancies, inducing durable tumor regressions and improved survival in multiple preclinical models of NHL and B-ALL. Based on these data, a phase 1 clinical trial evaluating SGN-CD19B in NHL is planned to start in 2016.
